Investor Relations

About Tempramed

TempraMed is a leading medical device technology company transforming medication management for individuals with chronic conditions. Its innovative solutions combine advanced hardware and digital technologies to protect temperature-sensitive medications and empower patients with unprecedented health control.

Leveraging patented temperature control technology and sophisticated digital platforms, TempraMed ensures medication potency, enables precise tracking, and facilitates information sharing between patients, caregivers, and healthcare providers.

Patented Technology

The company’s cutting-edge devices protect critical medications while simplifying treatment management. Committed to improving patient outcomes, TempraMed bridges the gap between medical device engineering and digital health innovation. The company provides intuitive solutions that help patients with chronic conditions live more confidently.

Why Invest

Untapped Market Potential:

Over 160 million patients use temperature sensitive medications every day globally; $30BN total addressable market (TAM).

Proprietary, Patented Technology:

8 patents globally. Space grade technology that keeps medication at optimal temperatures. First protective storage solution that is compact, hassle-free and user friendly, battery free, works 24/7/365, no maintenance required. Over hundreds of thousands of VIVI Caps sold to date, ~30% of customers repeat buys, high customer satisfaction rate.

Global Distribution Capabilities:

Manufactured in the USA with current production capacity of 1M units/year (~US$70 million in sales), assembly facility in Israel & international distribution capabilities with centers in Texas, Dubai, Mumbai (and expanding).

Strong Validation & Market Adoption:

Distribution with large pharmacy, government and retail networks including: Humana, CVS, Walmart, Walgreens, Amazon, McKesson, Target, US Department of Veteran Affairs

Aggressive Growth Strategy with Robust Pipeline:

Future distribution partnerships, expanding product portfolio, entering new market verticals

Strong Recurring Revenue Profile:

US$2.2 Million in 2024, projected rev. of +US$5.0M in 2025, ~US$19M in 2026 and cash flow positive

Recent Press Releases

recent2.jpg__PID:184eab53-2774-4c77-a7c3-c4822c9a017d

June 25, 2025

Strategic Distribution Partnership

May 26, 2025

Quarter-Over-Quarter Revenue Growth

May 22, 2025

TempraMed Corporate Update

Sign Up for
Investor Updates

You have successfully subscribed!
This email has been registered